Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO
Late last week Spero Therapeutics threw its S-1 into the IPO ring as the biotech queue for jumping into the public arena was growing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
